During Prostate Cancer Awareness Month, we are reminded that Cabrini stands at the forefront of ground-breaking research and treatment, offering hope to thousands of Australian men affected by this pervasive disease.

Prostate cancer remains the most diagnosed cancer in Australian men, with alarming statistics:

• 1 in 12 men will be diagnosed with prostate cancer by age 70
• 1 in 5 men will face a prostate cancer diagnosis in their lifetime
• Approximately 25,500 new cases are diagnosed in Australia each year
• Tragically, 10 men die each day from prostate cancer

The hospital’s Department of Urology, led by the esteemed Professor Mark Frydenberg AM, treats an impressive 700 prostate cancer patients annually representing 13% of all cases in Victoria.

“Our vision is clear,” states Professor Frydenberg. “We aim to improve both survival rates and quality of life for patients with prostate cancer. This involves enhancing early detection, reducing treatment side-effects, expanding options for advanced cases, minimising invasive interventions, and providing personalised care.”

Cabrini’s Department of Urology is revolutionising prostate cancer research through five key pillars:

1. Preclinical Models: The MURAL Collection, a library of patient-derived xenografts, allows researchers to replicate the diverse biology of prostate cancer in laboratory settings.
2. Theranostics: In partnership with GenesisCare, Cabrini is pioneering the use of theranostics—a cutting-edge approach that combines diagnostics and therapeutics to precisely target cancer cells.
3. Precision Therapies: The Cabrini Focal Therapy Database is enhancing patient selection for targeted treatments, while research into radioligand therapy aims to make this treatment accessible to more patients.
4. Advanced Imaging: Cabrini leads in the application of MRI and PET/CT scans for improved diagnostic accuracy and treatment guidance.
5. Machine Learning: Collaboration on projects like ArteraAI is streamlining diagnoses through sophisticated AI models, revolutionising how prostate cancer is detected and assessed.

As we commemorate Prostate Cancer Awareness Month, Cabrini’s work reminds us of the power of research and innovation. However, this vital endeavour relies heavily on the generosity of donors who understand that today’s investments pave the way for tomorrow’s breakthroughs.

Cabrini’s Department of Urology, in partnership with Monash University BDI, are reducing the burden of prostate cancer and improving outcomes for countless Australian men and their families.

Remember, early detection saves lives. This Prostate Cancer Awareness Month, let’s spread the word, support cutting-edge research, and stand united in the fight against prostate cancer.

Learn more about Cabrini Urology Department.